Molina Healthcare stock holds near 200 USD as guidance cut refocuses investors on margins

Molina Healthcare stock remains close to 200 USD as of September 1, 2026, while investors weigh a recent full-year EPS guidance cut and the latest earnings beat against tighter margins and an elevated valuation.

Molina Healthcare stock (ISIN US60855R1005) is trading close to the 200 USD mark as of September 1, 2026, with recent data showing the shares at 198.43 USD on the New York Stock Exchange while the average analyst price target stands at 202.44 USD according to MarketBeat data cited in a recent overview dated September 1, 2026. In the same period, health insurance peers in the United States have also attracted interest, as defensive stocks in the sector rose on September 1, 2026, when broader equity benchmarks came under pressure and bond yields moved higher, highlighting renewed attention on managed care names.

Guidance cut and valuation under scrutiny

According to an analysis of Molina Healthcare published on September 1, 2026, the company reduced its full-year 2026 adjusted earnings per share guidance to 5.25 USD, down from expectations that had been above 14 USD a year earlier, a change that significantly lowers the profit outlook for the current fiscal year. The same analysis notes that despite this cut, the stock still traded at an adjusted forward price-to-earnings multiple of about 157 times, a level that underscores how sensitive the shares may be to any further shifts in margins or earnings delivery in 2026. In that context, investors are closely watching whether the latest earnings beat in the most recent quarter, reported in July 2026, can be repeated in the second half of the year as the company balances growth in premium revenue with cost pressures.

Market data compiled in early September 2026 indicate that Molina Healthcare stock is around 19 percent below its 52-week high, a sign that the shares have already corrected from prior peaks even after delivering a gain of about 46.4 percent over a recent five-month period. For comparison, a late August 2026 snapshot cited by a stock-portal article showed the shares at 200.03 USD on August 31, 2026, implying that the current level near 198.43 USD as of September 1, 2026 has left the price slightly below that late-August close and suggesting a modest pullback into early September. For investors, the quantified combination of a roughly 19 percent distance from the 52-week high and a still-elevated earnings multiple is now central to assessing the risk-reward balance.

Earnings beat and revenue scale in 2026

In its latest reported quarter for 2026, detailed in a July 2026 earnings update, Molina Healthcare delivered an earnings beat versus market expectations, helping to support the stock near the 200 USD level into the start of September 2026. According to that July 2026 report as summarized by a financial portal, the company reaffirmed or highlighted a premium revenue guidance figure of approximately 42 billion USD for the full year 2026, positioning the group as a major player in Medicaid and Medicare managed care with substantial top-line scale. The same source noted that this revenue guidance compares to lower revenue figures achieved in prior years, underscoring that even with the guidance cut on earnings, Molina Healthcare is still targeting higher absolute premium volumes in 2026 than in earlier reporting periods.

From a profitability perspective, the July 2026 earnings release indicated that margins in the latest quarter remained under pressure compared with historical highs even as earnings per share came in above consensus estimates. The earnings beat, in combination with the later guidance reduction down to 5.25 USD in expected full-year EPS, means that the implied back-half earnings contribution will need to bridge the gap between the strong second-quarter result and the more conservative full-year level. This quantified gap between a successful quarter and a trimmed annual target is a central theme for analysts who are now revisiting their models and debating whether the current margin trough can be reversed in 2027.

Analyst view and index context

Data compiled by MarketBeat and referenced in an update on September 2, 2026 show that Molina Healthcare currently carries an average analyst rating categorized as Hold, with an average price target of 202.44 USD based on recent coverage. With the stock at 198.43 USD as of September 1, 2026, that consensus target implies upside of about 2.0 percent relative to the latest quoted level, a modest gap that signals neither a strongly bullish nor strongly bearish stance from the analyst community at this stage. Some analysts have pointed to the combination of the 5.25 USD EPS guidance for 2026 and the roughly 157 times forward adjusted price-to-earnings ratio as reasons for caution, particularly when compared with other managed-care peers that trade at lower multiples.

On September 1, 2026, a market commentary noted that Molina Healthcare and several peers such as Elevance Health, the Cigna Group, and UnitedHealth Group closed the session higher, with Molina Healthcare shares rising by more than 2 percent on that day as investors rotated into defensive health insurance names while broader indices fell. For investors with a diversified view of the sector, this relative resilience adds context to the company-specific numbers: Molina Healthcare stock may be down about 19 percent from its 52-week high, but on individual sessions like September 1, 2026 it can still outperform the wider market when risk-off sentiment leads to a search for defensive growth. In this sense, the stock’s behavior within the broader S and P 500 health-care universe is as important as its own guidance and valuation metrics.

Medicaid and Medicare managed care focus

Molina Healthcare is a managed-care company that primarily provides health plans to beneficiaries of Medicaid and Medicare, as well as to individuals and families who purchase coverage through government exchanges. In its latest reporting, the company highlighted premium revenue guidance of around 42 billion USD for 2026, reflecting continued expansion across multiple U.S. states and programs. This premium base is driven largely by contracts with state agencies, where Molina Healthcare administers benefits for low-income and high-need populations, and where performance is closely tied to both medical-cost trends and regulatory frameworks.

Within this business model, the company’s margins are influenced by medical-loss ratios, administrative expenses, and the terms of capitation payments from state and federal programs. The July 2026 quarterly update emphasized that while revenue growth remains robust, higher medical costs and adjustments in state funding have constrained margins compared with earlier years. For investors, the key operational question is whether the current 2026 premium revenue guidance of 42 billion USD can be delivered without further erosion in profitability, particularly given the explicit cut in EPS guidance to 5.25 USD for the full year. Historical figures from prior fiscal years, such as earlier revenue levels below 40 billion USD, serve mainly as a comparison point, underlining that the company is now operating at a larger scale with different risk parameters.

Stock position and market metrics

As of August 31, 2026, a detailed stock-portal snapshot reported that Molina Healthcare stock closed at 200.03 USD, giving the company a market capitalization of 10.44 billion USD at that time and placing the shares 18.0 percent below their 52-week high of 244.89 USD and 65.2 percent above their 52-week low of 121.06 USD. These figures provide a concrete sense of where the shares stand: in late August 2026 the price was in the upper half of the 52-week range but still significantly below the peak, capturing both the prior rally and the subsequent partial retracement. With the latest cited price of 198.43 USD as of September 1, 2026, the market capitalization would remain close to that 10.44 billion USD level, assuming no material change in share count, and the stock would continue to trade within a similar band relative to its 52-week high and low.

For investors tracking the stock on the New York Stock Exchange under the ticker MOH, these market metrics can be combined with the fundamental guidance to form a quantitative picture of risk and potential reward. On the one hand, trading at about 19 percent below the 52-week high suggests that the stock has room to recover if earnings stabilize and margins improve; on the other hand, the combination of a 5.25 USD EPS target for 2026 and an adjusted forward price-to-earnings multiple of 157 times indicates limited margin of safety if guidance were to be cut again. The interplay of these numbers means that even moderate surprises in quarterly results can have an outsized impact on the share price.

Molina Healthcare at a glance

• Company: Molina Healthcare, Inc.
• ISIN: US60855R1005
• Ticker: MOH
• Trading venue: NYSE
• Price (as of September 1, 2026): 198.43 USD
• Market capitalization: 10.44 billion USD (as of August 31, 2026)
• Sector / Industry: Health Care / Managed Health Care
• Index membership: S and P 500